Masaaki Eto

Summary

Affiliation: Kawasaki Medical School
Country: Japan

Publications

  1. ncbi Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients
    Masaaki Eto
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Am J Kidney Dis 40:243-51. 2002
  2. ncbi Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan
    M Eto
    Department of Medicine, Kawasaki Medical School, Kurashiki, Japan
    Clin Genet 61:416-22. 2002
  3. ncbi Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes
    Mieko Saito
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Metabolism 51:964-9. 2002
  4. ncbi Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients
    Mieko Saito
    Diabetes and Endocrine Division, Department of Internal Medicine, Kawasaki Medical School, Matsushima 577, Kurashiki 701 0192, Japan
    Diabetes Care 27:1276-80. 2004
  5. ncbi Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes
    Masafumi Matsuda
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama ken 701 0192
    Eur J Pharmacol 453:141-8. 2002
  6. ncbi Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells
    Takemi Otsuki
    Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama 701 0192, Japan
    Oncol Rep 11:1053-8. 2004
  7. ncbi IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor
    Takemi Otsuki
    Department of Hygiene, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Int J Oncol 23:763-8. 2003
  8. ncbi Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review
    Junichi Mukai
    Department of Pharmacy, Akita University Hospital, 1 1 1 Hondo Akita, Akita 010 8543, Japan
    Yakugaku Zasshi 127:1747-56. 2007
  9. ncbi [Case of familial hypoalphalipoproteinemia, type 2 diabetes mellitus and markedly advanced atherosclerosis with ABCAlexon 4 minus transcript in macrophages]
    Mieko Saito
    Moleculan Biology Kawasaki Medical School, Kurashiki
    Nihon Naika Gakkai Zasshi 91:2762-4. 2002
  10. ncbi Plasma lipid levels and nutritional intake in childhood- and adolescence-onset young type 1 diabetic patients in Japan
    Mieko Saito
    School of Pharmaceutical Sciences, Ohu University and Department of Medicine, Ohu University Hospital, Tomita Misumido 31 1, Koriyama 963 8611, Japan
    Diabetes Res Clin Pract 73:29-34. 2006

Collaborators

Detail Information

Publications10

  1. ncbi Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients
    Masaaki Eto
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Am J Kidney Dis 40:243-51. 2002
    ..The aim of the present study is to further investigate the association between apo E genetic polymorphism, plasma lipid levels (particularly remnant lipoproteins), and diabetic nephropathy...
  2. ncbi Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan
    M Eto
    Department of Medicine, Kawasaki Medical School, Kurashiki, Japan
    Clin Genet 61:416-22. 2002
    ..The patients were characterized by a high frequency of obesity and/or glucose intolerance. The TG-rich lipoproteins from type III HLP patients with diabetes mellitus were more atherogenic...
  3. ncbi Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes
    Mieko Saito
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Metabolism 51:964-9. 2002
    ..RLP from apo E2/2 diabetes with type III HLP are more atherogenic than those from apo E2/2 nondiabetes with type III HLP...
  4. ncbi Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients
    Mieko Saito
    Diabetes and Endocrine Division, Department of Internal Medicine, Kawasaki Medical School, Matsushima 577, Kurashiki 701 0192, Japan
    Diabetes Care 27:1276-80. 2004
    ..The aim of this study was to investigate the effect of apolipoprotein (apo)E4 allele on plasma LDL cholesterol response to calorie-restricted diet therapy in type 2 diabetic patients...
  5. ncbi Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes
    Masafumi Matsuda
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama ken 701 0192
    Eur J Pharmacol 453:141-8. 2002
    ..Our results strongly suggest the possibility that chronic intervention with an ATP-sensitive K(+) channel opener prevents the progress of deranged beta-cell function even after the development of diabetes mellitus...
  6. ncbi Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells
    Takemi Otsuki
    Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama 701 0192, Japan
    Oncol Rep 11:1053-8. 2004
    ..Based on these findings, statins may be suitable for clinical usage in maintenance therapy for myeloma patients...
  7. ncbi IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor
    Takemi Otsuki
    Department of Hygiene, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Int J Oncol 23:763-8. 2003
    ..Indeed, rhIL-6 abolished pravastatin-induced growth inhibition in KMS-21BM cells which did not express IL-6. Statins may be useful in maintenance therapy for myeloma after the screening of IL-6 status...
  8. ncbi Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review
    Junichi Mukai
    Department of Pharmacy, Akita University Hospital, 1 1 1 Hondo Akita, Akita 010 8543, Japan
    Yakugaku Zasshi 127:1747-56. 2007
    ..The improving effect of (III) on serum lipids may be clinically effective for considering the pathologic condition of diabetes, which is often complicated by hyperlipidemia...
  9. ncbi [Case of familial hypoalphalipoproteinemia, type 2 diabetes mellitus and markedly advanced atherosclerosis with ABCAlexon 4 minus transcript in macrophages]
    Mieko Saito
    Moleculan Biology Kawasaki Medical School, Kurashiki
    Nihon Naika Gakkai Zasshi 91:2762-4. 2002
  10. ncbi Plasma lipid levels and nutritional intake in childhood- and adolescence-onset young type 1 diabetic patients in Japan
    Mieko Saito
    School of Pharmaceutical Sciences, Ohu University and Department of Medicine, Ohu University Hospital, Tomita Misumido 31 1, Koriyama 963 8611, Japan
    Diabetes Res Clin Pract 73:29-34. 2006
    ..5g/day, p<0.01) than the childhood group. It is concluded that young Japanese type 1 diabetic patients with onset of adolescence have lipid abnormalities, which may be mainly caused by westernized dietary habits...